BeiGene Q4 product revenue $339M (+72% YoY); BRUKINSA sales $176M (+101%); tislelizumab gets 10th China approval

BeOne Medicines Ltd.

2022-FY EPS reported -$1.49 revenue$1,415,921,000

Product revenue $339M Q4, $1.3B FY2022, up 72% and 98% YoY; net loss $445M Q4, $2.0B FY.
BRUKINSA global sales $176M Q4 (+101%), $565M FY (+159%); U.S. sales $125M Q4 (+124%).
Tislelizumab China sales $102M Q4 (+88%), $423M FY (+66%); NMPA approved 10th indication for first-line gastric cancer.
Cash $4.5B at Dec 31, 2022; operating cash burn $1.5B FY.
BRUKINSA received U.S. FDA approval for CLL/SLL in Jan 2023; EC approval for CLL.

item 2.02 item 8.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

BeOne Medicines Ltd. reported full year 2022 results: revenue $1.4 billion.

Period: full year 2022
Revenue: $1.4 billion
Result: reported results

Exact text from the filing

Revenue for the fourth quarter and full year 2022 was $380.1 million and $1.4 billion, respectively

View on SEC.gov

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

BeOne Medicines Ltd. reported fourth quarter 2022 results: revenue $380.1 million.

Period: fourth quarter 2022
Revenue: $380.1 million
Result: reported results

Exact text from the filing

Revenue for the fourth quarter and full year 2022 was $380.1 million and $1.4 billion, respectively

View on SEC.gov

Browse all earnings releases →

BeOne Medicines Ltd. filing history →

Source: SEC EDGAR

accession 0001651308-23-000031

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.